APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Viral Vector-Based Cell & Gene Therapy CDMO

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Viral Vector-Based Cell & Gene Therapy CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174266870315 April 2026186 pages

Choose your research edition.

Industry ResearchViral Vector-Based Cell & Gene Therapy CDMO Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Vector-Based Cell & Gene Therapy CDMO Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Viral Vector-Based Cell & Gene Therapy CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Vector-Based Cell & Gene Therapy CDMO Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Viral Vector-Based Cell & Gene Therapy CDMO Market Analysis and Forecast 2026-2032229 pages · $4,950 USD

Market perspective

The global Viral Vector-Based Cell & Gene Therapy CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Viral Vector-Based Cell & Gene Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Viral Vector-Based Cell & Gene Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Viral Vector-Based Cell & Gene Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Viral Vector-Based Cell & Gene Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Viral Vector-Based Cell & Gene Therapy CDMO include AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco and Exothera, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Viral Vector-Based Cell & Gene Therapy CDMO market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Viral Vector-Based Cell & Gene Therapy CDMO and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Viral Vector-Based Cell & Gene Therapy CDMO revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Viral Vector-Based Cell & Gene Therapy CDMO market size, projected growth trends, production technologies, key applications, and end-use industries.

Viral Vector-Based Cell & Gene Therapy CDMO Segment by Company

AGC Biologics

Lonza

Charles River Laboratories

Thermo Fisher Scientific

SK pharmteco

Exothera

Viral Vector-Based Cell & Gene Therapy CDMO Segment by Type

Adeno-associated Viral

Adenoviral

Lentiviral

Retroviral

Viral Vector-Based Cell & Gene Therapy CDMO Segment by Application

Gene Therapy

Cell Therapy

Vaccine Development

Viral Vector-Based Cell & Gene Therapy CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vector-Based Cell & Gene Therapy CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Vector-Based Cell & Gene Therapy CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vector-Based Cell & Gene Therapy CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Viral Vector-Based Cell & Gene Therapy CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Viral Vector-Based Cell & Gene Therapy CDMO industry.

Chapter 3: Detailed analysis of Viral Vector-Based Cell & Gene Therapy CDMO companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Vector-Based Cell & Gene Therapy CDMOrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Adeno-associated Viral Table 3. Key Players of Adenoviral Table 4. Key Players of Lentiviral Table 3. Key Players of Retroviral Table 4. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Gene Therapy Table 6. Key Players of Cell Therapy Table 7. Key Players of Vaccine Development Table 8. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region (2021-2026) Table 11. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region (2027-2032) Table 13. Viral Vector-Based Cell & Gene Therapy CDMO Industry Trends Table 14. Viral Vector-Based Cell & Gene Therapy CDMO Industry Drivers Table 15. Viral Vector-Based Cell & Gene Therapy CDMO Industry Opportunities and Challenges Table 16. Viral Vector-Based Cell & Gene Therapy CDMO Industry Restraints Table 17. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Company (2021-2026) Table 19. Global Viral Vector-Based Cell & Gene Therapy CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Viral Vector-Based Cell & Gene Therapy CDMO Key Company Head Office and Area Served Table 21. Global Viral Vector-Based Cell & Gene Therapy CDMO Company, Product Type & Application Table 22. Global Viral Vector-Based Cell & Gene Therapy CDMO Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Viral Vector-Based Cell & Gene Therapy CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Type (2021-2026) Table 29. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Type (2027-2032) Table 30. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Application (2021-2026) Table 34. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Application (2027-2032) Table 35. AGC Biologics Company Information Table 36. AGC Biologics Business Overview Table 37. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 39. AGC Biologics Recent Development Table 40. Lonza Company Information Table 41. Lonza Business Overview Table 42. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 44. Lonza Recent Development Table 45. Charles River Laboratories Company Information Table 46. Charles River Laboratories Business Overview Table 47. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 49. Charles River Laboratories Recent Development Table 50. Thermo Fisher Scientific Company Information Table 51. Thermo Fisher Scientific Business Overview Table 52. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 54. Thermo Fisher Scientific Recent Development Table 55. SK pharmteco Company Information Table 56. SK pharmteco Business Overview Table 57. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 59. SK pharmteco Recent Development Table 60. Exothera Company Information Table 61. Exothera Business Overview Table 62. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 64. Exothera Recent Development Table 65. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021-2026) & (US$ Million) Table 66. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2027-2032) & (US$ Million) Table 67. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021-2026) & (US$ Million) Table 68. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2027-2032) & (US$ Million) Table 69. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 70. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026) Table 71. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032) Table 72. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021-2026) & (US$ Million) Table 73. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2027-2032) & (US$ Million) Table 74. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021-2026) & (US$ Million) Table 75. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2027-2032) & (US$ Million) Table 76. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 77. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026) Table 78. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032) Table 79. China Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021-2026) & (US$ Million) Table 80. China Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2027-2032) & (US$ Million) Table 81. China Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021-2026) & (US$ Million) Table 82. China Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2027-2032) & (US$ Million) Table 83. Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021-2026) & (US$ Million) Table 84. Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2027-2032) & (US$ Million) Table 85. Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021-2026) & (US$ Million) Table 86. Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2027-2032) & (US$ Million) Table 87. Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026) Table 89. Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032) Table 90. South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021-2026) & (US$ Million) Table 91. South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2027-2032) & (US$ Million) Table 92. South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021-2026) & (US$ Million) Table 93. South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2027-2032) & (US$ Million) Table 94. South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026) Table 96. South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032) Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Viral Vector-Based Cell & Gene Therapy CDMO Product Image Figure 2. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Type: 2025 VS 2032 Figure 4. Adeno-associated Viral Image Figure 5. Adenoviral Image Figure 6. Lentiviral Image Figure 7. Retroviral Image Figure 8. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 9. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Application: 2025 VS 2032 Figure 10. Gene Therapy Image Figure 11. Cell Therapy Image Figure 12. Vaccine Development Image Figure 13. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 15. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region: 2025 VS 2032 Figure 16. Years Considered Figure 17. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Players in 2025 Figure 18. Global Top 5 and 10 Viral Vector-Based Cell & Gene Therapy CDMO Players Market Share by Revenue in 2025 Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Type (2021-2032) Figure 22. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Application (2021-2032) Figure 24. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 25. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Type (2021-2032) Figure 26. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Application (2021-2032) Figure 27. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032) Figure 28. United States Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 29. Canada Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 30. Mexico Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 31. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 32. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Type (2021-2032) Figure 33. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Application (2021-2032) Figure 34. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032) Figure 35. Germany Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 36. France Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 37. U.K. Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 38. Italy Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 39. Russia Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 40. Nordic Countries Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 41. China Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 42. China Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Type (2021-2032) Figure 43. China Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Application (2021-2032) Figure 44. Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 45. Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Type (2021-2032) Figure 46. Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Application (2021-2032) Figure 47. Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032) Figure 48. Japan Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 49. South Korea Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 50. Taiwan Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 51. Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 52. India Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 53. Australia Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Type (2021-2032) Figure 56. South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Application (2021-2032) Figure 57. South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032) Figure 58. Brazil Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 59. South Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 61. Turkey Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 62. Argentina Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 63. UAE Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 64. Egypt Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 65. Chile Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Adeno-associated Viral
  • Adenoviral
  • Lentiviral
  • Retroviral
Applications
  • Gene Therapy
  • Cell Therapy
  • Vaccine Development
Companies covered
  • AGC Biologics
  • Lonza
  • Charles River Laboratories
  • Thermo Fisher Scientific
  • SK pharmteco
  • Exothera

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Adeno-associated Viral
  5. 1.2.3 Adenoviral
  6. 1.2.4 Lentiviral
  7. 1.2.5 Retroviral
  8. 1.3 Market Analysis by Application
  9. 1.3.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  10. 1.3.2 Gene Therapy
  11. 1.3.3 Cell Therapy
  12. 1.3.4 Vaccine Development
  13. 1.4 Global Market Growth Prospects
  14. 1.5 Global Viral Vector-Based Cell & Gene Therapy CDMO Growth Trends by Region
  15. 1.5.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region: 2021 VS 2025 VS 2032
  16. 1.5.2 Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2021-2026)
  17. 1.5.3 Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2027-2032)
  18. 1.6 Assumptions and Limitations
  19. 1.7 Study Goals and Objectives
  20. 1.8 Years Considered
2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Dynamics
  1. 2.1 Viral Vector-Based Cell & Gene Therapy CDMO Industry Trends
  2. 2.2 Viral Vector-Based Cell & Gene Therapy CDMO Industry Drivers
  3. 2.3 Viral Vector-Based Cell & Gene Therapy CDMO Industry Opportunities and Challenges
  4. 2.4 Viral Vector-Based Cell & Gene Therapy CDMO Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Company (2021-2026)
  2. 3.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Key Company Head office and Area Served
  4. 3.4 Global Viral Vector-Based Cell & Gene Therapy CDMO Company, Product Type & Application
  5. 3.5 Global Viral Vector-Based Cell & Gene Therapy CDMO Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Viral Vector-Based Cell & Gene Therapy CDMO Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Viral Vector-Based Cell & Gene Therapy CDMO Tier 1, Tier 2, and Tier 3
4 Viral Vector-Based Cell & Gene Therapy CDMO Market by Type
  1. 4.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021-2032)
  3. 4.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share by Type (2021-2032)
5 Viral Vector-Based Cell & Gene Therapy CDMO Market by Application
  1. 5.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021-2032)
  3. 5.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 AGC Biologics
  2. 6.1.1 AGC Biologics Company Information
  3. 6.1.2 AGC Biologics Business Overview
  4. 6.1.3 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  6. 6.1.5 AGC Biologics Recent Developments
  7. 6.2 Lonza
  8. 6.2.1 Lonza Company Information
  9. 6.2.2 Lonza Business Overview
  10. 6.2.3 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  12. 6.2.5 Lonza Recent Developments
  13. 6.3 Charles River Laboratories
  14. 6.3.1 Charles River Laboratories Company Information
  15. 6.3.2 Charles River Laboratories Business Overview
  16. 6.3.3 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  18. 6.3.5 Charles River Laboratories Recent Developments
  19. 6.4 Thermo Fisher Scientific
  20. 6.4.1 Thermo Fisher Scientific Company Information
  21. 6.4.2 Thermo Fisher Scientific Business Overview
  22. 6.4.3 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  24. 6.4.5 Thermo Fisher Scientific Recent Developments
  25. 6.5 SK pharmteco
  26. 6.5.1 SK pharmteco Company Information
  27. 6.5.2 SK pharmteco Business Overview
  28. 6.5.3 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  30. 6.5.5 SK pharmteco Recent Developments
  31. 6.6 Exothera
  32. 6.6.1 Exothera Company Information
  33. 6.6.2 Exothera Business Overview
  34. 6.6.3 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  36. 6.6.5 Exothera Recent Developments
7 North America
  1. 7.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032)
  2. 7.2 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type
  3. 7.2.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021-2026)
  4. 7.2.2 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2027-2032)
  5. 7.2.3 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Type (2021-2032)
  6. 7.3 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application
  7. 7.3.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021-2026)
  8. 7.3.2 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2027-2032)
  9. 7.3.3 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Application (2021-2032)
  10. 7.4 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country
  11. 7.4.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026)
  13. 7.4.3 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032)
  14. 7.4.4 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032)
  2. 8.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type
  3. 8.2.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021-2026)
  4. 8.2.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2027-2032)
  5. 8.2.3 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Type (2021-2032)
  6. 8.3 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application
  7. 8.3.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021-2026)
  8. 8.3.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2027-2032)
  9. 8.3.3 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Application (2021-2032)
  10. 8.4 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country
  11. 8.4.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026)
  13. 8.4.3 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032)
  14. 8.4.4 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032)
  2. 9.2 China Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type
  3. 9.2.1 China Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021-2026)
  4. 9.2.2 China Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2027-2032)
  5. 9.2.3 China Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Type (2021-2032)
  6. 9.3 China Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application
  7. 9.3.1 China Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021-2026)
  8. 9.3.2 China Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2027-2032)
  9. 9.3.3 China Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032)
  2. 10.2 Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type
  3. 10.2.1 Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021-2026)
  4. 10.2.2 Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2027-2032)
  5. 10.2.3 Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Type (2021-2032)
  6. 10.3 Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application
  7. 10.3.1 Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021-2026)
  8. 10.3.2 Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2027-2032)
  9. 10.3.3 Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Application (2021-2032)
  10. 10.4 Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country
  11. 10.4.1 Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026)
  13. 10.4.3 Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032)
  14. 10.4.4 Asia Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst